Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab
ConclusionThis is the first described case of grade 4 immune mucositis and esophagitis associated with pembrolizumab. Because the use of pembrolizumab is increasing in oncology, pharmacists and physicians should be aware of this rare manifestation.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Head and Neck Cancer | HNSCC | Immunotherapy | Laryngeal Cancer | Methylprednisolone | Oral Cancer | Oral Cavity Cancer | Pharyngeal Cancer | Prednisone | Skin Cancer | Squamous Cell Carcinoma